MiR-30a-5p inhibits osteosarcoma cell proliferation and migration by targeting FOXD1

被引：45

作者：

Tao, Jun ^{[1
]}

Cong, Haibo ^{[2
]}

Wang, Hongyan ^{[2
]}

Zhang, Daoqiang ^{[2
]}

Liu, Chuanjie ^{[2
]}

Chu, Hongxia ^{[2
]}

Qing, Qianfeng ^{[2
]}

Wang, Kunzheng ^{[1
]}

机构：

[1] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Orthoped, Xian 710004, Shaanxi, Peoples R China

[2] Weihai Cent Hosp, Weihai City Key Lab Autoimmun, Weihai 264400, Shandong, Peoples R China

来源：

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS | 2018年 / 503卷 / 02期

基金：

中国国家自然科学基金;

关键词：

Osteosarcoma; FOXD1; miR-30a-5p; Cell proliferation; Cell migration; BREAST-CANCER; GROWTH; SUPPRESSES; APOPTOSIS; MICRORNAS; PROGNOSIS; GENETICS; STAND;

D O I：

10.1016/j.bbrc.2018.06.121

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Despite a number of studies have emphasized the extensive role of microRNA (miRNA) in the development of multiple cancers, the role of miR-30a-5p in the progression of osteosarcoma (OS) and the underlying mechanism are still limited. We detected the expression level of MiR-30a-5p and forkhead box D1 (FOXD1) in Clinical OS specimens and found that miR-30a-5p was significantly decreased while FOXD1 was markedly increased. Dual luciferase assay confirmed that FOXD1 was directly regulated by miR-30a-5p. In vitro assay showed that inhibitior of FOXD1 suppressed cell proliferation, migration and invasion in MG63 and U2OS cells, while overexpression of FOXD1 promoted OS cell proliferation and migration. In vivo assay further showed the inhibition of tumor growth after knockdown of FOXD1. These results suggested that FOXD1 might play key roles in OS development and progression, and was negatively regulated by miR-30a-5p in OS. (C) 2018 Published by Elsevier Inc.

引用

页码：1092 / 1097

页数：6

共 24 条

[1] Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand? [J].

Anninga, Jakob K. ;

Gelderblom, Hans ;

Fiocco, Marta ;

Kroep, Judith R. ;

Taminiau, Anstoni H. M. ;

Hogendoorn, Pancras C. W. ;

Egeler, R. Maarten .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) :2431-2445

[2] MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer [J].

Bertoli, Gloria ;

Cava, Claudia ;

Castiglioni, Isabella .

THERANOSTICS, 2015, 5 (10) :1122-1143

[3] Postoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma [J].

Chen, Yu ;

Xu, Song-Feng ;

Xu, Ming ;

Yu, Xiu-Chun .

MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (03) :495-500

[4] FOXD1 promotes nephron progenitor differentiation by repressing decorin in the embryonic kidney [J].

Fetting, Jennifer L. ;

Guay, Justin A. ;

Karolak, Michele J. ;

Iozzo, Renato V. ;

Adams, Derek C. ;

Maridas, David E. ;

Brown, Aaron C. ;

Oxburgh, Leif .

DEVELOPMENT, 2014, 141 (01) :17-27

[5] MiR-30a-5p connects EWS-FLI1 and CD99, two major therapeutic targets in Ewing tumor [J].

Franzetti, G-A ;

Laud-Duval, K. ;

Bellanger, D. ;

Stern, M-H ;

Sastre-Garau, X. ;

Delattre, O. .

ONCOGENE, 2013, 32 (33) :3915-3921

[6]

Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705

[7]

He RQ, 2015, INT J CLIN EXP PATHO, V8, P15632

[8] Cancer genetics and genomics of human FOX family genes [J].

Katoh, Masuko ;

Igarashi, Maid ;

Fukuda, Hirokazu ;

Nakagama, Hitoshi ;

Katoh, Masaru .

CANCER LETTERS, 2013, 328 (02) :198-206

[9] Prognostic value of microRNAs in osteosarcoma: A meta-analysis [J].

Kim, Yun Hak ;

Goh, Tae Sik ;

Lee, Chi-Seung ;

Oh, Sae Ock ;

Kim, Jeung Il ;

Jeung, Seung Hyeon ;

Pak, Kyoungjune .

ONCOTARGET, 2017, 8 (05) :8726-8737

[10] Foxd1 is a mediator and indicator of the cell reprogramming process [J].

Koga, Makito ;

Matsuda, Mitsuhiro ;

Kawamura, Teruhisa ;

Sogo, Takahiro ;

Shigeno, Asako ;

Nishida, Eisuke ;

Ebisuya, Miki .

NATURE COMMUNICATIONS, 2014, 5

← 1 2 3 →